Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1994-01-19
1995-10-31
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
562492, 560 53, 514530, A61K 3119
Patent
active
054629683
ABSTRACT:
The invention relates to (.+-.) trans-2-[-4(1-hydroxyhexyl) phenyl]-5-oxocyclopentaneheptanoic acid, and ester and unsaturated derivatives thereof, prostaglandin derivatives. More particularly, the present invention concerns compounds of the formula I ##STR1## wherein the wavy bonds indicate that .alpha. or .beta. configuration, the dashed bond represents either a single or double bond, which double bond may be a cis or trans double bond and R is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.m R.sub.1 wherein m is 0-10, and R.sub.1 is an aliphatic ring having from about 3 to about 7 carbon atoms, or an aryl or heteroaryl ring having from about 4 to about 10 carbon atoms and wherein the heteroatom is selected from the group consisting of N, O and S. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.
REFERENCES:
patent: 4494274 (1985-02-01), Chan et al.
patent: 4599353 (1986-07-01), Bito
patent: 5034413 (1991-07-01), Chan et al.
Weeldon et al., Br. J. Pharmacol. (1993), 108(4), 1051-4.
Niols et al., Br. J. Pharmacol., 102, 24P (1991).
Starr. M. S., "Further Studies on the Effect of Prostalgnadin on Intraocular Pressure in the Rabbit", Exp. Eye Research, 1971, 11, pp. 170-177.
Bito, L. Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents," Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et. al., "PGF.sub.2.alpha. Increases Uveoscleral Outflow", Invest. Ophthalmol. Vis. Sci. (suppl), 284, 1987.
Siebold, et al., "Esterified prostaglandin shows `potent` promise", Prodrug 5 3, 1989.
Bito, L. Z., "Prostaglandins, Old Concepts and New Perspectives", Arch. Ophthalmol. 105, 1036, 1987.
Coleman, R. A., et al., "Prostanoids and their Receptors", Comprehensive Medicinal Chemistry, vol. 3, pp. 643-714, 1990.
Woodward et al, "Identification of 19 (R) --OH Prostaglandin E.sub.2 as a Selective Prostanoid EP.sub.2 -Receptor Agonist", Prostaglandins, pp. 371-383, 1993.
Nials et al, "AH13205, A Selective Prostanoid EP.sub.2 -receptor Agonist", Cardiovascular Drug Reviews, vol. 11, No. 2, pp. 165-179 (1993).
Allergan Inc.
Baran Robert J.
Hoch J. Mark
Peabody John
Richter Johann
LandOfFree
EP.sub.2 -receptor agonists as agents for lowering intraocular p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP.sub.2 -receptor agonists as agents for lowering intraocular p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP.sub.2 -receptor agonists as agents for lowering intraocular p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1772735